Navigation Links
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:5/13/2008

CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

"Interim data recently presented from our U.K. Phase I dose escalation trial of REOLYSIN(R) in combination with paclitaxel and carboplatin indicated strong and durable responses in patients with advanced head and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics. "We believe it is important to further explore these findings by conducting a Phase II trial in this specific patient population."

This trial is a 14 patient, single arm, open-label, dose-targeted, non-randomized, multi-centre trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Patients with a variety of advanced cancers, including head and neck cancers, will continue to be treated in the ongoing U.K. combination paclitaxel and carboplatin trial.

Eligible patients include those with advanced or metastatic head and neck cancer that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytic
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Vernon Hills, Ill. (PRWEB) May 16, 2013 ... including benchtop and portable models, from Cole-Parmer is ... professionals. The enhanced line includes: , The new ... that are true workhorses in the lab. They ... superior serum and plasma specimen separation. Their standard ...
(Date:5/16/2013)... May 16, 2013  The registration deadline has been ... Officers (ABFO) 2013 National Conference, the premier conference for ... 28-31 at the Hilton San Diego Bayfront. ... year,s conference and want to make sure as many ... Brandi Roberts , Chief Financial Officer ...
(Date:5/16/2013)... YORK , May 16, 2013 ... new market research report is available ... Competitor Analysis: Therapeutic ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The new ...
(Date:5/16/2013)... Dr. Stephen Y. Chou, Founder of Nanonex ... and Applications” at IEEE Nano 2013 in Beijing, China, ... by Chou, is becoming one of the most critical ... sub-10 nm resolution, large area, and low cost unmatchable ... and manufacturing in a broad range of industries, from ...
Breaking Biology Technology:Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... , STOCKHOLM, ... European Investment Fund (EIF) has entered into a,co-investment agreement ... Karolinska Development and used to invest in the company,s,portfolio ... to invest 26.7 M Euros in the co-investment fund. ...
... Most people would like to be able to charge ... not too often. A recent discovery made by UC ... that could do just this. In recent ... Bandaru, a professor in the UCSD Department of Mechanical ...
... , BETHESDA, Md., Nov. 19 ... for diabetes therapy, and a provider of technical and regulatory ... today it closed the previously reported $6.3 million registered direct ... stock and warrants to purchase up to 1,104,348 additional shares ...
Cached Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
(Date:5/18/2013)... 2013) The AGA Research Foundation is honored to ... Award in Digestive Cancer, which will support Andrew D. ... the University of Pennsylvania, Philadelphia, as he furthers his ... regeneration and cancer progression. , "The AGA Research Foundation ... two distinguished clinicians and AGA Legacy Society members," said ...
(Date:5/18/2013)... 2013) Research presented today at Digestive Disease Week ... findings about the impact of coffee on autoimmune disease ... coffee consumption recently has been associated with reduced risk ... few more cups of java each month also correlate ... Researchers at the Mayo Clinic, Rochester, MN, linked coffee ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) Research presented ... for managing digestive health through diet and lifestyle. ... often plagued by reduced muscle strength, fatigue and ... even when patients are in remission. A randomized, ... time that vitamin D supplementation corresponded to significant ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
... A groundbreaking study lead by Chapman University professor Brennan ... will be published in the May 5th edition ... reproductive biology. It is the first such study ... the USA, the postponement of childbearing is reflective of ...
... The American Academy of OtolaryngologyHead and Neck Surgery (AAO-HNS) ... physicians. Clinical indicators for otolaryngology serve as a checklist ... clinical departments. The Clinical Indicators are created by the ... define a basis of medical necessity for a range ...
... LSU,s Mark Batzer, along with research associate Jerilyn Walker and ... orangutans are host to ancient jumping genes called Alu, which ... done in collaboration with the Zoological Society of San Diego ... featured in the new open access journal Mobile DNA ...
Cached Biology News:New study published on fertility awareness among American university students 2LSU research finds orangutans host ancient jumping genes 2
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
Biology Products: